Evidence map›Paper›PMID 33221422›Full record

SynthesisMagnetic resonance imaging2021

Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Hosamadin Assadi, Rachel Jones, Andrew J Swift, Abdallah Al-Mohammad, Pankaj Garg

Registry-linked trialOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Magnetic resonance imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270367 (Finerenone and Cardiac Remodeling), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07270367 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling

TypeinterventionalSponsorSubodh VermaRan2025 to 2030Enrolled156ConditionsHeart FailureArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Imaging Advances in Heart Failure.Cardiac failure review · 2024
    Review
  14. Article
  15. Emerging molecular imaging targets and tools for myocardial fibrosis detection.European heart journal. Cardiovascular Imaging · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hosamadin AssadiDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Rachel JonesDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Andrew J SwiftDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Abdallah Al-MohammadDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
Pankaj GargDepartment of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK. Electronic address: pankaj.garg@nhs.net.
University of Sheffield · GB

Funding

Wellcome Trust 205188/Z/16/ZWellcome Trust 220703/Z/20/Z
6 · The paper itself

Abstract

backgroundCardiac magnetic resonance imaging (MRI) is emerging as an important imaging tool in the assessment of heart failure with preserved ejection fraction (HFpEF). This systematic review and meta-analysis aim to synthesise and consolidate the current literature on cardiac MRI for prognostication of HFpEF. METHODS

designSystematic review and meta-analysis. DATA SOURCES: Scopus (PubMed and Embase) for studies published between 2008 and 2019. Eligibility criteria for study selection were studies that evaluated the prognostic role of cardiac MRI in HFpEF. Random effects meta-analyses of the reported hazard ratios (HR) for clinical outcomes was performed.

resultsInitial screening identified 97 studies. From these, only nine (9%) studies met all the criteria. The main cardiac MRI methods that demonstrated association to prognosis in HFpEF included late gadolinium enhancement (LGE) assessment of scar (n = 3), tissue characterisation with T1-mapping (n = 4), myocardial ischaemia (n = 1) and right ventricular dysfunction (RVSD) (n = 1). The pooled HR for all 9 studies was 1.52 (95% CI 1.05-1.99, P < 0.01). Sub-evaluation by cardiac MRI methods revealed varying HRs: LGE (net n = 402, HR = 1.6, 95% CI 0.42-2.78, P = 0.008); T1-mapping (n = 1623, HR = 1.25, 95% CI 0.891-1.60, P < 0.001); myocardial ischaemia or RVSD (n = 325, HR = 3.19, 95% CI 0.30-6.08, P = 0.03).

conclusionThis meta-analysis demonstrates that multiparametric cardiac MRI has value in prognostication of patients with HFpEF. HFpEF patients with a detectable scar on LGE, fibrosis on T1-mapping, myocardial ischaemia or RVSD appear to have a worse prognosis. PROSPERO REGISTRATION NUMBER: CRD42020187228.

Indexed as

Magnetic Resonance ImagingStroke VolumeHeartHeart FailureHumansPrognosisCardiac MRIHeart failureHFpEFLate gadolinium enhancementPrognosisT1 mapping

Identifiers

PMID33221422
PMCPMC7819363
OpenAlexW3103831866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.